In May 2012, the US Preventive Services Task Force (USPSTF) recommended against prostate-specific antigen (PSA)–based screening for prostate cancer, giving it a grade D and concluding, “there is moderate certainty that the benefits of PSA-based screening from prostate cancer do not outweigh the harms.”1 Rather than put an end to this controversy over screening, this recommendation further fueled a contentious ongoing debate.
Penson DF. The Pendulum of Prostate Cancer Screening. JAMA. 2015;314(19):2031-2033. doi:10.1001/jama.2015.13775